MYL News and Press, Mylan N.V. From 06/08/20

Since the local market bottom on March 23rd, 2020, the S&P 500 ( SPY ) has rallied a remarkable 43%. The gains have not all come from the megacaps. A version of the S&P 500 that equal-weights the constituents ( RSP ) has done even better, rallying roughly 54%. Source: Bloomberg The...

Amid the coronavirus-fueled market downturn -- and the economic troubles that have followed -- many companies have slashed or outright suspended their dividend payments, much to the dismay of income-seeking investors. However, some companies look poised to ride out the current market downturn wi...

The coronavirus outbreak has been a major theme in the stock market these past few months. Investors bet on companies working on treatment and prevention, and some shares -- particularly those of clinical-stage biotech players -- skyrocketed. Now the question is whether it's too late to invest ...

HERTFORDSHIRE, England , PITTSBURGH and MUMBAI, India , June 4, 2020 /PRNewswire/ --  Mylan N.V.  (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Commission (EC) has granted marketing authorization for Nepexto ® , a biosimilar to Enbrel &#x...

Despite disruptions from the COVID-19 pandemic, Momenta Pharmaceuticals ' (NASDAQ: MNTA) clinical trials investigating experimental therapies for a variety of autoimmune conditions and rare diseases are still going strong. The company will be announcing top-line phase 2 results for the treat...

It is no secret that prescription drug prices in America are the highest among all developed nations. A variety of factors have contributed to the issue, such as a lack of universal healthcare coverage, the staggering cost of conducting clinical trials to get drugs to approval, and price gougin...

Quick Take Avidity Biosciences ( RNA ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing treatments for diseases including various dystrophies and Pompe disease. RNA is a very early stage firm but has a sig...

- First neurotoxin formulation to be developed as a potential biosimilar product to BOTOX ® , potentially giving Mylan access to 14 indications upon approval - - $30 million milestone payable to Revance from Mylan - Revance Therapeutics, Inc. (NASDAQ: RVNC) and Mylan N.V. (NASDAQ...

HERTFORDSHIRE, England and PITTSBURGH , May 29, 2020 /PRNewswire/ -- Mylan N.V.  (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi's Lant...

Antares Pharma (NASDAQ: ATRS) is one of the fastest-growing biotech stocks in the sector, with multiple collaboration agreements with large-cap pharmaceutical companies to supply it with pressure-assisted injector devices. The wheel of fortune, however, has not been kind to Antares, as its ...